Nu Holdings dominates Brazil's underbanked, high-fee banking oligopoly with a differentiated, tech-driven model. Click to ...
Zacks Investment Research on MSN
Can NVO defend its obesity lead as GLP-1 competition intensifies?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for diabetes) and Wegovy (for obesity). Despite being NVO’s key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback